Rigel Pharmaceuticals Inc (RIGL) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Rigel Pharmaceuticals Inc  (NASDAQ: RIGL)


Rigel Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Rigel Pharmaceuticals Inc's ROI in the second quarter of 2026?
Rigel Pharmaceuticals Inc achieved a return on average invested assets (ROI) of 89 % in its second quarter of 2026, this is above RIGL's average return on investment of -36.28%.
Rigel Pharmaceuticals Inc invested over the 12 months ending in its second quarter of 2026 $362 million

ROI fell compared to the first quarter of 2026, despite the net income growth of 99.79% from the first quarter of 2026.

Within the Healthcare sector 13 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Jun 30 2026 quarter, so far to 32, from total ROI ranking in the first quarter of 2026 at 33.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 242.44 % 194.96 % 150.5 % 102.77 % 90.84 %
Y / Y Net Income Change TTM 229.08 % 879.7 % 1326.33 % 894.64 % -
Investment (TTM) in Millions 469 415 414 148 120
Return On Investment (TTM) 89 % 132.72 % 185.38 % 93.34 % 92.61 %
RIGL's Overall Ranking # 32 # 33 # 21 # 44 # 21
Seq. Investment Change TTM 31.8 % 38.61 % 63.11 % 14.92 % 13.53 %
Seq. Net Income Change TTM -11.62 % -0.76 % 223.94 % 15.82 % 163.12 %
Net Income (TTM) in Millions 322 364 367 113 98

RIGL Company Profile >> Back to RIGL Roi Comparisons >> See Annual RIGL Return On Investment



Return On Investment RIGL's Ranking
Within: No.
Industry # 5
Sector # 14
Overall # 32

Return On Investment Statistics
High Average Low
185.38 %
-36.28 %
-115.42 %
(Dec 31 2025)   (Sep 30 2022)







Financial Statements
Rigel Pharmaceuticals Inc's II. Quarter Investments $ 469 Millions RIGL's Balance sheet
Rigel Pharmaceuticals Inc's II. Quarter Income $ 17 Millions Quarterly RIGL's Income Statement
RIGL's Income by Division See RIGL's Income by Division


RIGL Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 414 101 31 69 104
Y / Y Investment Growth 311.57 % 222.13 % -54.75 % -33.44 % 49.24 %
Net Income in Millions 367 17 -25 -59 -18
Y / Y Net Income Growth 1999.08 % - - - -
Annual Return On Investment 88.58 % 17.37 % -80.28 % -84.8 % -17.26 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 88.58 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
RIGL's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for RIGL's Competitors
Subscribers only: Roi for Rigel Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for RIGL's Customers

Other Ratios
RIGL's Roa RIGL's Inventory Turnover Ratio RIGL's Growth Rates RIGL's Dividend Statistics
RIGL's Profitability Ratios RIGL's Asset Turnover Ratio RIGL's Dividend Growth
RIGL's Roe RIGL's Valuation Ratios RIGL's Financial Strength Ratios RIGL's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI
Omeros Corporation  198.34 %
Elutia Inc   191.75 %
Sanuwave Health Inc   167.92 %
Vor Biopharma Inc   162.71 %
Capforce Inc   161.42 %
Kyntra Bio Inc   157.74 %
Silexion Therapeutics Corp  127.60 %
Quince Therapeutics Inc   112.49 %
Pulmatrix Inc   108.83 %
Interpace Biosciences Inc   100.71 %
Rigel Pharmaceuticals Inc  89.00 %
Oncotelic Therapeutics Inc   87.35 %
Arbutus Biopharma Corp  85.89 %
Actinium Pharmaceuticals Inc  84.38 %
Exelixis Inc   82.05 %
Lensar Inc   75.31 %
Ironwood Pharmaceuticals inc   70.54 %
Oramed Pharmaceuticals Inc  68.90 %
Indivior Pharmaceuticals Inc   68.79 %
Rallybio Corporation  68.28 %
Fortress Biotech Inc   68.27 %
Earth Science Tech Inc   64.38 %
Meiragtx Holdings Plc  55.83 %
Elite Pharmaceuticals Inc   53.48 %
Idexx Laboratories Inc  51.80 %
Aurinia Pharmaceuticals Inc   50.35 %
Qhslab Inc   48.94 %
Q32 Bio Inc   47.43 %
Vaxart Inc   46.17 %
Liquidia Corporation  42.09 %

Date modified: 2026-09-26T07:14:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.